vTv Therapeutics
VTVT
30 hedge funds and large institutions have $2.47M invested in vTv Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
11% more funds holding
Funds holding: 27 → 30 (+3)
0.01% more ownership
Funds ownership: 0.11% → 0.11% (+0.01%)
27% less capital invested
Capital invested by funds: $3.38M → $2.47M (-$919K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
V
Veritable
Wilmington,
Delaware
|
+$184K |
| 2 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$47.7K |
| 3 |
DT
Diversified Trust
Memphis,
Tennessee
|
+$15.4K |
| 4 |
HF
HRT Financial
New York
|
+$13.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$24.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22K |
| 3 |
VF
Virtu Financial
New York
|
-$17.7K |
| 4 |
Millennium Management
New York
|
-$10.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| $326 | – | – | – |
|
|
CA
27
CoreCap Advisors
Southfield,
Michigan
| $249 | +$298 | +9 | New |
|
28
BNP Paribas Financial Markets
Paris,
France
| $219 | – | – | – |
|
29
Bank of America
Charlotte,
North Carolina
| $46 | +$66 | +2 | New |
|
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$22K | -556 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$4K | -114 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$33 | -1 | -25% |
|
VTVT Hedge Fund Activity: Q4 2022 in Review
30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2022, worth a combined $2.47M — down 27% from $3.38M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VTVT positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Veritable, adding an estimated $184K. The largest seller was Prudential Financial, cutting an estimated $24.5K.
- 30 institutional investors held vTv Therapeutics (VTVT) as of Q4 2022, up from 27 in Q3 2022.
- Funds reported $2.47M of vTv Therapeutics stock for Q4 2022, down 27% quarter-over-quarter.
- 6 funds opened new vTv Therapeutics positions in Q4 2022 and 3 closed out, a net change of +3 holders.
- The largest vTv Therapeutics buyer in Q4 2022 was Veritable, an estimated $184K added.
- The largest vTv Therapeutics seller in Q4 2022 was Prudential Financial, an estimated $24.5K sold.
Based on aggregated 13F filings for Q4 2022.